Inhibition of HIV Env binding to cellular receptors by monoclonal antibody 2G12 as probed by Fc-tagged gp120

Retrovirology

Volumn 3, Issue , 2006, Pages

  Binley, James M ^a   Ngo Abdalla, Stacie ^b   Moore, Penny ^c   Bobardt, Michael ^b   Chatterji, Udayan ^b   Gallay, Philippe ^b   Burton, Dennis R ^b   Wilson, Ian A ^b   Elder, John H ^b   de Parseval, Aymeric ^b  

^a TORREY PINES INSTITUTE FOR MOLECULAR STUDIES   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOHYDRATE; CD209 ANTIGEN; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; EPITOPE; FC RECEPTOR; GLYCOPROTEIN GP 160; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2G12; SYNDECAN; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS FUSION PROTEIN; VIRUS RECEPTOR;

ANIMAL CELL; ARTICLE; BINDING ASSAY; CELL LINE; CONTROLLED STUDY; DENDRITIC CELL; DRUG TARGETING; GENE DELETION; HOST RESISTANCE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VIVO STUDY; INFECTION RESISTANCE; MOLECULAR PROBE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SEQUENCE TAGGED SITE; VIRUS ADSORPTION; VIRUS CELL INTERACTION; VIRUS INHIBITION; VIRUS NEUTRALIZATION; WILD TYPE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD4; CELL ADHESION MOLECULES; CELL LINE; DENDRITIC CELLS; DOGS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HELA CELLS; HEPARAN SULFATE PROTEOGLYCANS; HIV ENVELOPE PROTEIN GP120; HUMANS; LECTINS, C-TYPE; MICE; PROTEIN BINDING; RECEPTORS, CCR5; RECEPTORS, CELL SURFACE; RECEPTORS, FC; RECEPTORS, HIV; RECOMBINANT FUSION PROTEINS;

EID: 33747325494     PISSN: 17424690     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-3-39     Document Type: Article

References (88)

1. Poignard P, Saphire EO, Parren PW, Burton DR: gp 120: Biologic aspects of structural features. Annu Rev Immunol 2001, 19:253-274.
2. Burton DR, Pyati J, Koduri R, Sharp SJ, Thornton GB, Parren PW, Sawyer LS, Hendry RM, Dunlop N, Nara PL, et al.: Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994, 266(5187):1024-1027.
3. Scanlan CN, Pantophlet R, Wormald MR, Saphire EO, Calarese D, Stanfield R, Wilson IA, Katinger H, Dwek RA, Burton DR, Rudd PM: The carbohydrate epitope of the neutralizing anti-HIV-1 antibody 2G12. Adv Exp Med Biol 2003, 535:205-218.
4. Scanlan CN, Pantophlet R, Wormald MR, Ollmann Saphire E, Stanfield R, Wilson IA, Katinger H, Dwek RA, Rudd PM, Burton DR: The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of al ->2 mannose residues on the outer face of gp120. J Virol 2002, 76(14):7306-7321.
5. Calarese DA, Scanlan CN, Zwick MB, Deechongkit S, Mimura Y, Kunert R, Zhu P, Wormald MR, Stanfield RL, Roux KH, Kelly JW, Rudd PM, Dwek RA, Katinger H, Burton DR, Wilson IA: Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 2003, 300(5628):2065-2071.
6. Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, Sullivan N, Srinivasan K, Sodroski J, Moore JP, Katinger H: Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol 1996, 70(2):1100-1108.
7. Sanders RW, Venturi M, Schiffner L, Kalyanaraman R, Katinger H, Lloyd KO, Kwong PD, Moore JP: The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp 120. J Viral 2002, 76(14):7293-7305.
8. Stiegler G, Kunert R, Purtscher M, Wolbank S, Voglauer R, Steindl F, Katinger H: A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 2001, 17(18):1757-1765.
9. Zwick MB, Labrijn AF, Wang M, Spenlehauer C, Saphire EO, Binley JM, Moore JP, Stiegler G, Katinger H, Burton DR, Parren PW: Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 2001, 75(22):101892-10905.
10. Muster T, Steindl F, Purtscher M, Trkola A, Klima A, Himmler G, Ruker F, Katinger H: A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 1993, 67(11):6642-6647.
11. Parker CE, Deterding LJ, Hager-Braun C, Binley JM, Schulke N, Katinger H, Moore JP, Tomer KB: Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5. J Virol 2001, 75(22):10906-10911.
12. de Rosny E, Vassell R, Jiang S, Kunert R, Weiss CD: Binding of the 2F5 monoclonal antibody to native and fusion-intermediate forms of human immunodeficiency virus type 1 gp41: implications for fusion-inducing conformational changes. J Virol 2004, 78(5):2627-2631.
13. Zwick MB, Saphire EO, Burton DR: gp41: HIV's shy protein. Nat Med 2004, 10(2):133-134.
14. Ugolini S, Mondor I, Sattentau QJ: HIV-1 attachment: another look. Trends Microbiol 1999, 7(4):144-149.
15. Spenlehauer C, Kirn A, Aubertin AM, Moog C: Antibody-mediated neutralization of primary human immunodeficiency virus type 1 isolates: investigation of the mechanism of inhibition. J Virol 2001, 75(5):2235-2245.
16. Ugolini S, Mondor I, Parren PW, Burton DR, Tilley SA, Klasse PJ, Sattentau QJ: Inhibition of virus attachment to CD4+ target cells is a major mechanism of T cell line-adapted HIV-1 neutralization. J Exp Med 1997, 186(8):1287-1298.
17. Mondor I, Ugolini S, Sattentau QJ: Human immunodeficiency virus type 1 attachment to HeLa CD4 cells is CD4 independent and gp120 dependent and requires cell surface heparans. J Virol 1998, 72(5):3623-3634.
18. Burrer R, Haessig-Einius S, Aubertin AM, Moog C: Polyclonal immunoglobulin G from patients neutralizes human immunodeficiency virus type 1 primary isolates by binding free virions, but without interfering with an initial CD4-independent attachment of the virus to primary blood mononuclear cells. J Virol 2003, 77(21):11385-11397.
19. Saphire AC, Bobardt MD, Zhang Z, David G, Gallay PA: Syndecans serve as attachment receptors for human immunodeficiency virus type 1 on macrophages. J Virol 2001, 75(19):9187-9200.
20. Bobardt MD, Saphire AC, Hung HC, Yu X, Van der Schueren B, Zhang Z, David G, Gallay PA: Syndecan captures, protects, and transmits HIV to T lymphocytes. Immunity 2003, 18(1):27-39.
21. Lee B, Leslie G, Soilleux E, O'Doherty U, Baik S, Levroney E, Flummerfelt K, Swiggard W, Coleman N, Malim M, Doms RW: cis Expression of DC-SIGN allows for more efficient entry of human and simian immunodeficiency viruses via CD4 and a coreceptor. J Virol 2001, 75(24):12028-12038.
22. Beirnaert E, De Zutter S, Janssens W, van der Groen G: Potent broad cross-neutralizing sera inhibit attachment of primary HIV-1 isolates (groups M and O) to peripheral blood mononuclear cells. Virology 2001, 281(2):305-314.
23. McInerney TL, Dimmock NJ: Postattachment neutralization of a primary strain of HIV type 1 in peripheral blood mononuclear cells is mediated by CD4-specific antibodies but not by a glycoprotein 120-specific antibody that gives potent standard neutralization. AIDS Res Hum Retroviruses 2001, 17(17):1645-1654.
24. Fortin JF, Cantin R, Tremblay MJ: T cells expressing activated LFA-1 are more susceptible to infection with human immunodeficiency virus type 1 particles bearing host-encoded ICAM-1. J Virol 1998, 72(3):2105-2112.
25. Geijtenbeek TB, Kwon DS, Torensma R, van Vliet SJ, van Duijnhoven GC, Middel J, Cornelissen IL, Nottet HS, KewalRamani VN, Littman DR, Figdor CG, van Kooyk Y: DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 2000, 100(5):587-597.
26. Fortin JF, Cantin R, Lamontagne G, Tremblay M: Host-derived ICAM-1 glycoproteins incorporated on human immunodeficiency virus type 1 are biologically active and enhance viral infectivity. J Virol 1997, 71(5):3588-3596.
27. Liao Z, Roos JW, Hildreth JE: Increased infectivity of HIV type 1 particles bound to cell surface and solid-phase ICAM-1 and VCAM-1 through acquired adhesion molecules LFA-1 and VLA-4. AIDS Res Hum Retroviruses 2000, 16(4):355-366.
28. Cantin R, Fortin JF, Lamontagne G, Tremblay M: The presence of host-derived HLA-DRI on human immunodeficiency virus type 1 increases viral infectivity. J Virol 1997, 71(3):1922-1930.
29. Bounou S, Dumais N, Tremblay MJ: Attachment of human immunodeficiency virus-1 (HIV-1) particles bearing host-encoded B7-2 proteins leads to nuclear factor-kappa B- and nuclear factor of activated T cells-dependent activation of HIV-1 long terminal repeat transcription. J Biol Chem 2001, 276(9):6359-6369.
30. Hildreth JE, Orentas RJ: Involvement of a leukocyte adhesion receptor (LFA-1) in HIV-induced syncytium formation. Science 1989, 244(4908):1075-1078.
31. Geijtenbeek TB, van Kooyk Y: DC-SIGN: a novel HIV receptor on DCs that mediates HIV-1 transmission. Curr Top Microbiol Immunol 2003, 276:31-54.
32. Pohlmann S, Leslie GJ, Edwards TG, Macfarlan T, Reeves JD, Hiebenthal-Millow K, Kirchhoff F, Baribaud F, Doms RW: DC-SIGN interactions with human immunodeficiency virus: virus binding and transfer are dissociable functions. J Virol 2001, 75(21):10523-10526.
33. Su SV, Gurney KB, Lee B: Sugar and spice: viral envelope-DC-SIGN interactions in HIV pathogenesis. Curr HIV Res 2003, 1(1):87-99.
34. McDonald D, Wu L, Bohks SM, KewalRamani VN, Unutmaz D, Hope TJ: Recruitment of HIV and its receptors to dendritic cell-T cell junctions. Science 2003, 300(5623):1295-1297.
35. Su SV, Hong P, Baik S, Negrete OA, Gurney KB, Lee B: DC-SIGN binds to HIV-1 glycoprotein 120 in a distinct but overlapping fashion compared with ICAM-2 and ICAM-3. J Biol Chem 2004, 279(18):19122-19132.
36. de Parseval A, Su SV, Elder JH, Lee B: Specific interaction of feline immunodeficiency virus surface glycoprotein with human DC-SIGN. J Virol 2004, 78(5):2597-2600.
37. Gurney KB, Elliott J, Nassanian H, Song C, Soilleux E, McGowan I, Anton PA, Lee B: Binding and transfer of human immunodeficiency virus by DC-SIGN+ cells in human rectal mucosa. J Virol 2005, 79(9):5762-5773.
38. Roderiquez G, Oravecz T, Yanagishita M, Bou-Habib DC, Mostowski H, Norcross MA: Mediation of human immunodeficiency virus type 1 binding by interaction of cell surface heparan sulfate proteoglycans with the V3 region of envelope gp120-gp41. J Virol 1995, 69(4):2233-2239.
39. Zhang YJ, Hatziioannou T, Zang T, Braaten D, Luban J, Goff SP, Bieniasz PD: Envelope-dependent, cyclophilin-independent effects of glycosaminoglycans on human immunodeficiency virus type 1 attachment and infection. J Virol 2002, 76(12):6332-6343.
40. Blanco J, Barretina J, Gutierrez A, Armand-Ugon M, Cabrera C, Clotet B, Este JA: Preferential attachment of HIV particles to activated and CD45RO+CD4+ T cells. AIDS Res Hum Retroviruses 2002, 18(1):27-38.
41. Guibinga GH, Miyanohara A, Esko JD, Friedmann T: Cell surface heparan sulfate is a receptor for attachment of envelope protein-free retrovirus-like particles and VSV-G pseudotyped MLV-derived retrovirus vectors to target cells. Mol Ther 2002, 5(5 Pt 1):538-546.
42. de Parseval A, Bobardt MD, Chatterji A, Chatterji U, Elder JH, David G, Zolla-Pazner S, Farzan M, Lee TH, Gallay PA: A highly conserved arginine in GP120 governs HIV-1 binding to both syndecans and CCR5 via sulfated motifs. J Biol Chem 2005, 280(47):39493-504.
43. Labriln AF, Poignard P, Raja A, Zwick MB, Delgado K, Franti M, Binley J, Vivona V, Grundner C, Huang CC, Venturi M, Petropoulos CJ, Wrin T, Dimitrov DS, Robinson J, Kwong PD, Wyatt RT, Sodroski J, Burton DR: Access of Antibody Molecules to the Conserved Coreceptor Binding Site on Glycoprotein gp120 Is Sterically Restricted on Primary Human Immunodeficiency Virus Type 1. J Virol 2003, 77(19):10557-10565.
44. Lusso P, Earl PL, Sironi F, Santoro F, Ripamonti C, Scarlatti G, Longhi R, Berger EA, Burastero SE: Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains. J Virol 2005, 79(11):6957-6968.
45. Crooks ET, Moore PL, Richman D, Robinson J, Crooks JA, Franti M, Schulke N, Binley JM: Characterizing anti-HIV monoclonal antibodies and immune sera by defining the mechanism of neutralization. Hum Antibodies 2005, 14(3-4):101-113.
46. Binley JM, Cayanan CS, Wiley C, Schulke N, Olson WC, Burton DR: Redox-triggered infection by disulfide-shackled human immunodeficiency virus type 1 pseudovirions. J Virol 2003, 77(10):5678-5684.
47. Mondor I, Moulard M, Ugolini S, Klasse PJ, Hoxie J, Amara A, Delaunay T, Wyatt R, Sodroski J, Sattentau QJ: Interactions among HIV gp120, CD4, and CXCR4: dependence on CD4 expression level, gp120 viral origin, conservation of the gp120 COOH-and NH2-termini and V1/V2 and V3 loops, and sensitivity to neutralizing antibodies. Virology 1998, 248(2):394-405.
48. McInerney TL, McLain L, Armstrong SJ, Dimmock NJ: A human IgG1 (b12) specific for the CD4 binding site of HIV-1 neutralizes by inhibiting the virus fusion entry process, but b12 Fab neutralizes by inhibiting a postfusion event. Virology 1997, 233(2):313-326.
49. McDougal JS, Nicholson JK, Cross GD, Cort SP, Kennedy MS, Mawle AC: Binding of the human retrovirus HTLV-III/LAV/ARV/HIV to the CD4 (T4) molecule: conformation dependence, epitope mapping, antibody inhibition, and potential for idiotypic mimicry. J Immunol 1986, 137(9):2937-2944.
50. Trkola A, Dragic T, Arthos J, Binley JM, Olson WC, Allaway GP, Cheng-Mayer C, Robinson J, Maddon PJ, Moore JP: CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature 1996, 384(6605):184-187.
51. Wu L, Gerard NP, Wyatt R, Choe H, Parolin C, Ruffing N, Borsetti A, Cardoso AA, Desjardin E, Newman W, Gerard C, Sodroski J: CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 1996, 384(6605):179-183.
52. Kolchinsky P, Mirzabekov T, Farzan M, Kiprilov E, Cayabyab M, Mooney LJ, Choe H, Sodroski J: Adaptation of a CCR5-using, primary human immunodeficiency virus type 1 isolate for CD4-independent replication. J Virol 1999, 73(10):8120-8126.
53. Raja A, Venturi M, Kwong P, Sodroski J: CD4 binding site antibodies inhibit human immunodeficiency virus gp120 envelope glycoprotein interaction with CCR5. J Virol 2003, 77(1):713-718.
54. Barouch DH, Santra S, Schmitz JE, Kuroda MJ, Fu TM, Wagner W, Bilska M, Craiu A, Zheng XX, Krivulka GR, Beaudry K, Lifton MA, Nickerson CE, Trigona WL, Punt K, Freed DC, Guan L, Dubey S, Casimiro D, Simon A, Davies ME, Chastain M, Strom TB, Gelman RS, Montefiori DC, Lewis MG, Emini EA, Shiver JW, Letvin NL: Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 2000, 290(5491):486-492.
55. Isaka Y, Akagi Y, Ando Y, Tsujie M, Sudo T, Ohno N, Border WA, Noble NA, Kaneda Y, Hori M, Imai E: Gene therapy by transforming growth factor-beta receptor-IgG Fc chimera suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney Int 1999, 55(2):465-475.
56. de Parseval A, Elder JH: Binding of recombinant feline immunodeficiency virus surface glycoprotein to feline cells: role of CXCR4, cell-surface heparans, and an unidentified non-CXCR4 receptor. J Virol 2001, 75(10):4528-4539.
57. Kurre P, Morris J, Miller AD, Kiem HP: Envelope fusion protein binding studies in an inducible model of retrovirus receptor expression and in CD34(+) cells emphasize limited transduction at low receptor levels. Gene Ther 2001, 8(8):593-599.
58. Herchenroder O, Moosmayer D, Bock M, Pietschmann T, Rethwilm A, Bieniasz PD, McClure MO, Weis R, Schneider J: Specific binding of recombinant foamy virus envelope protein to host cells correlates with susceptibility to infection. Virology 1999, 255(2):228-236.
59. Bergman I, Whitaker-Dowling P, Gao Y, Griffin JA, Watkins SC: Vesicular stomatitis virus expressing a chimeric Sindbis glycoprotein containing an Fc antibody binding domain targets to Her2/neu overexpressing breast cancer cells. Virology 2003, 316(2):337-347.
60. Hong PW, Flummerfelt KB, de Parseval A, Gurney K, Elder JH, Lee B: Human immunodeficiency virus envelope (gp120) binding to DC-SIGN and primary dendritic cells is carbohydrate dependent but does not involve 2G12 or cyanovirin binding sites: implications for structural analyses of gp120-DC-SIGN binding. J Virol 2002, 76(24):12855-12865.
61. Lekkerkerker AN, Ludwig IS, van Vliet SJ, van Kooyk Y, Geijtenbeek TB: Potency of HIV-1 envelope glycoprotein gp120 antibodies to inhibit the interaction of DC-SIGN with HIV-1 gp120. Virology 2004, 329(2):465-476.
62. Moore JP, Sodroski J: Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein. J Virol 1996, 70(3):1863-1872.
63. Binley JM, Wyatt R, Desjardins E, Kwong PD, Hendrickson W, Moore JP, Sodroski J: Analysis of the interaction of antibodies with a conserved enzymatically deglycosylated core of the HIV type 1 envelope glycoprotein 120. AIDS Res Hum Retroviruses 1998, 14(3):191-198.
64. Cormier EG, Dragic T: The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 enveolope glycoprotein interactions with the CCR5 coreceptor. J Virol 2002, 76(17):8953-8957.
65. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA: Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998, 393(6686):648-659.
66. Rizzuto C, Sodroski J: Fine definition of a conserved CCR5-binding region on the human immunodeficiency virus type 1 glycoprotein 120. AIDS Res Hum Retroviruses 2000, 16(8):741-749.
67. Gorny MK, Stamatatos L, Volsky B, Revesz K, Williams C, Wang XH, Cohen S, Staudinger R, Zolla-Pazner S: Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles. J Virol 2005, 79(8):5232-5237.
68. Xiang SH, Kwong PD, Gupta R, Rizzuto CD, Casper DJ, Wyatt R, Wang L, Hendrickson WA, Doyle ML, Sodroski J: Mutagenic Stabilization and/or Disruption of a CD4-Bound State Reveals Distinct Conformations of the Human Immunodeficiency Virus Type 1 gp120 Envelope Glycoprotein. J Virol 2002, 76(19):9888-9899.
69. Pinter A, Honnen WJ, D'Agostino P, Gorny MK, Zolla-Pazner S, Kayman SC: The C108g epitope in the V2 domain of gp120 functions as a potent neutralization target when introduced into envelope proteins derived from human immunodeficiency virus type 1 primary isolates. J Virol 2005, 79(11):6909-6917.
70. Moore PL, Crooks ET, Porter L, Zhu P, Cayanan CS, Grise H, Corcoran P, Zwick MB, Franti M, Morris L, Roux KH, Burton DR, Binley JM: Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J Virol 2006, 80(5):2515-2528.
71. Feinberg H, Mitchell DA, Drickamer K, Weis WI: Structural basis for selective recognition of oligosaccharides by DC-SIGN and DC-SIGNR. Science 2001, 294(5549):2163-2166.
72. Mitchell DA, Fadden AJ, Drickamer K: A novel mechanism of carbohydrate recognition by the C-type lectins DC-SIGN and DC-SIGNR. Subunit organization and binding to multivalent ligands. J Biol Chem 2001, 276(31):28939-28945.
73. Turville SG, Cameron PU, Handley A, Lin G, Pohlmann S, Doms RW, Cunningham AL: Diversity of receptors binding HIV on dendritic cell subsets. Nat Immunol 2002, 3(10):975-983.
74. Reece JC, Handley AJ, Anstee EJ, Morrison WA, Crowe SM, Cameron PU: HIV-1 selection by epidermal dendritic cells during transmission across human skin. J Exp Med 1998, 187(10):1623-1631.
75. Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, Hanson CE, Beary H, Hayes D, Frankel SS, Birx DL, Lewis MG: Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000, 6(2):207-210.
76. Tsai CC, Emau P, Jiang Y, Agy MB, Shattock RJ, Schmidt A, Morton WR, Gustafson KR, Boyd MR: Cyanovirin-N inhibits AIDS virus infections in vaginal transmission models. AIDS Res Hum Retroviruses 2004, 20(1):11-18.
77. Trkola A, Kuster H, Rusert P, Joos B, Fischer M, Leemann C, Manrique A, Huber M, Rehr M, Oxenius A, Weber R, Stiegler G, Vcelar B, Katinger H, Aceto L, Gunthard HF: Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med 2005, 11(6):615-622.
78. Binley JM, Wrin T, Korber B, Zwick MB, Wang M, Chappey C, Stiegler G, Kunert R, Zolla-Pazner S, Katinger H, Petropoulos CJ, Burton DR: Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol 2004, 78(23):13232-13252.
79. Zajonc DM, Elsliger MA, Teyton L, Wilson IA: Crystal structure of CD1a in complex with a sulfatide self antigen at a resolution of 2.15 A. Nat Immunol 2003, 4(8):808-815.
80. Conley AJ, Gorny MK, Kessler JA, Boots LJ, Ossorio-Castro M, Koenig S, Lineberger DW, Emini EA, Williams C, Zolla-Pazner S: Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D. J Virol 1994, 68(11):6994-7000.
81. Fung MS, Sun CR, Gordon WL, Liou RS, Chang TW, Sun WN, Daar ES, Ho DD: Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120. J Virol 1992, 66(2):848-856.
82. Nagashima KA, Thompson DA, Rosenfield SI, Maddon PJ, Dragic T, Olson WC: Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion. J Infect Dis 2001, 183(7):1121-1125.
83. Jacobson JM, Israel RJ, Lowy I, Ostrow NA, Vassilatos LS, Barish M, Tran DN, Sullivan BM, Ketas TJ, O'Neill TJ, Nagashima KA, Huang W, Petropoulos CJ, Moore JP, Maddon PJ, Olson WC: Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542. Antimicrob Agents Chemother 2004, 48(2):423-429.
84. Jacobson JM, Lowy I, Fletcher CV, O'Neill TJ, Tran DN, Ketas TJ, Trkola A, Klotman ME, Maddon PJ, Olson WC, Israel RJ: Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults. J Infect Dis 2000, 182(1):326-329.
85. Fouts TR, Binley JM, Trkola A, Robinson JE, Moore JP: Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex. J Virol 1997, 71(4):2779-2785.
86. Kolchinsky P. Kiprilov E, Sodroski J: Increased neutralization sensitivity of CD4-independent human immunodeficiency virus variants. J Virol 2001, 75(5):2041-2050.
87. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, Salazar-Gonzalez JF, Salazar MG, Kilby JM, Saag MS, Komarova NL, Nowak MA, Hahn BH, Kwong PD, Shaw GM: Antibody neutralization and escape by HIV-1. Nature 2003, 422(6929):307-312.
88. Connor RI, Chen BK, Choe S, Landau NR: Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology 1995, 206(2):935-944.